

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Combined oral and topical 5-ASA versus topical 5-ASA for the treatment of ulcerative proctitis.

Protocol summary

Summary

1- Objectives: Offering treatments with better performance and fewer side effects in patients with ulcerative proctitis. 2- Design: This is a clinical trial that will be performed in Health Centers of the Babol University of Medical Science. All of the patients will be selected based on both inclusion and exclusion criterias. 3- Setting and conduct: Before starting the study of each case a complete historical and physical examination as well as laboratory tests such as CBC, Cr, LFT and U/A will be done. The patients are randomly divided to two groups with 30 patients in each. 4- Participants including major eligibility criteria: Inclusion criteria: pateints older than 15 years old that have ulcerative colitis upon endoscopic and histologic criteria; severity of disease should be at least 3 of 12. Exclusion criteria: hypersensitivity to salicilate ; active PUD; important liver, renal or heart disease; patients not respond to 5-ASA and on maintenance therapy with 5-ASA . 5- Intervention: The patients of the intervention group are treated by 1 g Mesalazine suppository daily while the control group will be treated by both 3 g oral Mesalazine and 1 g Mesalazine suppository each day. The patients will be visited after four weeks of staring the study. Then, the screening will be continued every 3 mounts until 1 year. 6- Main outcome variables: clinical, endoscopic, and histopathologic response to each treatment strategies.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201604307080N3**

Registration date: **2016-10-25, 1395/08/04**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2016-10-25, 1395/08/04

Registrant information

Name

Javad Shokri Shirvani

Name of organization / entity

Babol University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 11 1223 8284

Email address

drshokrij@mubabol.ac.ir

Recruitment status

Recruitment complete

Funding source

university funding sources

Expected recruitment start date

2014-12-21, 1393/09/30

Expected recruitment end date

2016-09-20, 1395/06/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Combined oral and topical 5-ASA versus topical 5-ASA for the treatment of ulcerative proctitis.

Public title

Effect of mesalazine in treatment of distal inflammation of intestine.

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Patients older than 15 years old that have ulcerative colitis upon endoscopic and histologic criteria; severity of disease should be at least 3 of 12. Exclusion criteria: Hypersensitivity to salicylate; Active PUD; Important liver, renal or heart disease; Patients not respond to 5-ASA and on maintenance therapy with 5-ASA.

Age

From **15 years** old to **75 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Babol University of Medical Sciences

Street address

Vice president of research, University of Medical Sciences, Ganjafrooz Street

City

Babol

Postal code

47176-41367

Approval date

2016-01-31, 1394/11/11

Ethics committee reference number

MUBABOL.REC.1394.307

Health conditions studied**1****Description of health condition studied**

Ulcerative Colitis

ICD-10 code

K51

ICD-10 code description

Crohn disease of large intestine

Primary outcomes**1****Description**

Clinical response to each therapy groups

Timepoint

4 weeks after starting study then every 3 months until 1 year

Method of measurement

Disease Activity Index, Simple Clinical Colitis Activity Index Questionnaire

2**Description**

Endoscopic response to each therapy groups

Timepoint

4 weeks after starting study then every 3 months until 1 year

Method of measurement

Disease Activity Index, Simple Clinical Colitis Activity Index Questionnaire

3**Description**

Histopathologic response to each therapy groups

Timepoint

4 weeks after starting study then every 3 months until 1 year

Method of measurement

Disease Activity Index, Simple Clinical Colitis Activity Index Questionnaire

Secondary outcomes**1****Description**

Drug adverse reaction

Timepoint

4 weeks after starting of study then every 3 months until one year

Method of measurement

Questionnaire

2**Description**

Compliance to each treatment strategy

Timepoint

4 weeks after starting of study then every 3 months until one year

Method of measurement

Questionnaire

Intervention groups

1

Description

Intervention group will be treated with mesalazine suppository 500mg twice daily for one year.

Category

Treatment - Drugs

2

Description

Control group will be treated with oral mesalasin 500 mg two tablets three times daily and mesalasin suppository 500mg two times daily for one year.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Ayatollah Rouhani Hospital

Full name of responsible person

Aida Ghasempour

Street address

Internal Medicine Department, Ayatollah Rohani Hospital, Ganjafrooz street

City

Babol

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice Chancellor for research of Babol University of Medical Sciences

Full name of responsible person

Ali Bijani

Street address

University of Medical Sciences, Ganjafroz Street, Babol

City

Babol

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice Chancellor for research of Babol University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Babol University of Medical Sciences

Full name of responsible person

Aida Ghasempour

Position

Internal Medicine Resident

Other areas of specialty/work

Street address

Internal Medicine Department, Ayatollah Rohani Hospital, Ganjafrooz street

City

Babol

Postal code

47176-47745

Phone

+98 11 3199 5926

Fax

+98 11 3219 0181

Email

Aida_gh1985@yahoo.com

Web page address

<http://rohani.mubabol.ac.ir/>

Person responsible for scientific inquiries

Contact

Name of organization / entity

Babol University of Medical Sciences

Full name of responsible person

Aida Ghasempour

Position

Internal Medicine Resident

Other areas of specialty/work

Street address

Internal Medicine Department, Ayatollah Rohani Hospital, Ganjafrooz street

City

Babol

Postal code

47176-47745

Phone

+98 11321995926

Fax

+98 11 3219 0181

Email

Aida_gh1985@yahoo.com

Web page address

<http://rohani.mubabol.ac.ir/>

Person responsible for updating data

Contact

Name of organization / entity

Babol University of Medical Sciences

Full name of responsible person

Aida Ghasempour

Position

Internal Medicine Resident

Other areas of specialty/work**Street address**

Internal Medicine Department, Ayatollah Rouhani

Hospital, Ganjafrooz street

City

Babol

Postal code

47176-47745

Phone

+98 11321995926

Fax

+98 11 3219 0181

Email

aida_gh1985@yahoo.com

Web page address

<http://rohani.mubabol.ac.ir/>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty